We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

This study is currently recruiting participants.
Verified September 2017 by Roger Tell, Karolinska University Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT01946373
First Posted: September 19, 2013
Last Update Posted: September 27, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Roger Tell, Karolinska University Hospital
  Purpose
The purpose of this study is to learn if dendritic cell vaccine will increase the effect of tumor infiltrating lymphocytes given with chemotherapy and interleukin-2 in patients with melanoma.

Condition Intervention Phase
Melanoma Drug: Cyclophosphamide Drug: Fludarabine Biological: T cells Biological: Interleukin-2 Biological: Dendritic cell vaccine Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Roger Tell, Karolinska University Hospital:

Primary Outcome Measures:
  • Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0 [ Time Frame: 30 days ]

Secondary Outcome Measures:
  • Time to disease progression assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. [ Time Frame: 4 weeks ]

Estimated Enrollment: 10
Actual Study Start Date: October 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Chemotherapy + T cells + IL-2
Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses.
Drug: Cyclophosphamide
Other Names:
  • Sendoxan
  • Cytoxan
  • Neosar
Drug: Fludarabine
Other Names:
  • Fludarabine phosphate
  • Fludara
Biological: T cells Biological: Interleukin-2
Other Names:
  • IL-2
  • Proleukin
Experimental: Chemotherapy + T cells + IL-2 + DCV
Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
Drug: Cyclophosphamide
Other Names:
  • Sendoxan
  • Cytoxan
  • Neosar
Drug: Fludarabine
Other Names:
  • Fludarabine phosphate
  • Fludara
Biological: T cells Biological: Interleukin-2
Other Names:
  • IL-2
  • Proleukin
Biological: Dendritic cell vaccine

Detailed Description:

The MAT02 clinical trial is a phase 1 clinical trial with the objective to assess the safety, feasibility and immunological efficacy of the combined application of two immunological treatment modalities in patients with metastatic melanoma:

  1. Cohort A: After a non-myeloablative conditioning regimen, 5 patients will receive one bulk infusion of T cells. T cells will be expanded ex vivo from autologous tumor infiltrating lymphocytes (TIL). In vivo persistence of the infused cells will be supported by administration of IL-2, a T cell survival factor.
  2. Cohort B: This adoptive cell transfer (ACT) step will in additional 5 patients be followed by a vaccination with autologous, in vitro-generated, dendritic cells (DC), loaded with autologous tumor lysate and a synthetically produced peptide derived from the tumor associated antigen NY-ESO 1.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with measurable (direct on body surface or by x-ray and/or CT) malignant melanoma, that is advanced, inoperable stage III (advanced regional lymph node metastases, or more than 5 in-transit metastases, N2) or stage IV (distant metastasis, M1) according to the AJCC classification and confirmed by histology/cytology and appropriate radiological investigations.
  • Patients with a palpable resectable lesion located in the skin or in a lymph node or a lesion accessible by (core) biopsy. The lesion should be confirmed to be melanoma by fine needle biopsy.
  • Disease should be in progression and the patient should have exhausted other approved therapeutic options.
  • Ambulatory performance status (ECOG 0, 1, 2).
  • Age 18-74 and life expectancy greater than 3 months.
  • Patients must have been evaluated with imaging studies (MRI/CT/US/PET-CT) to establish metastasis/advanced disease in the period of 30 days prior to the initiation of the trial.

Exclusion Criteria:

  • Any of the above criteria are not met.
  • Significant history or current evidence of cardiovascular disease (e.g. uncontrolled congestive heart failure or hypertension, unstable coronary artery disease or serious arrhythmias) or major respiratory diseases. In questionable cases, a stress test should be performed.
  • Recipients of a major organ allograft. Autoimmune diseases such as, but not limited to, inflammatory bowel disease or multiple sclerosis. Vitiligo is not an exclusion criterion. Other serious chronic diseases.
  • Other serious illnesses, e.g. active infections requiring antibiotics, bleeding disorders.
  • Has had prior systemic cancer therapy within the past four weeks at the time of the start of the lymphodepletion regimen.
  • Patients diagnosed with prior malignancies (except adequately treated basal cell carcinomas of the skin or in situ carcinomas of the skin or in situ carcinomas of the cervix, surgically cured).
  • Patients with second advanced malignancies concurrently.
  • CNS metastases. (Note: Patients with brain metastases that have been completely resected at least one month prior to registration or have undergone gamma knife treatment with no evidence of recurrence on CT and who are neurologically stable, are not excluded).
  • Organic brain syndrome or significant psychiatric disorder which would preclude participation in the full protocol and follow-up.
  • Immunodeficiency, previous splenectomy or radiation therapy of the spleen.
  • Screening laboratory values:

    a) Inadequate hematologic function defined by: i) White blood count (WBC) <3.0 x 109/l ii) Platelet count <100x109/l iii) Hemoglobin level <100 g/l b) Inadequate hepatic function as defined by either: i) Total bilirubin level >1.5 times the upper limit of normal (ULN) ii) Aspartate amino transferase (AST) or alanine amino transferase (ALT) >3 times the ULN (if related to liver metastases >5 times the ULN) c) Inadequate renal function defined as serum creatinine >1.5 times the ULN

  • Infectious diseases that can be transmitted via contact with blood, such as HIV, Hepatitis B and C.
  • Women who are pregnant or nursing will be excluded because of the potentially dangerous effects of the preparative chemotherapy on the fetus.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01946373


Contacts
Contact: Roger Tell, MD, PhD +46760293911 roger.tell@ki.se
Contact: Rolf Kiessling, MD, PhD +46733428848 rolf.kiessling@ki.se

Locations
Sweden
Karolinska University Hospital Recruiting
Stockholm, Sweden, SE-171 76
Contact: Roger Tell, MD, PhD    +46760293911    roger.tell@ki.se   
Principal Investigator: Roger Tell, MD, PhD         
Sponsors and Collaborators
Karolinska University Hospital
Investigators
Principal Investigator: Roger Tell, MD, PhD Karolinska University Hospital
  More Information

Responsible Party: Roger Tell, Dr, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT01946373     History of Changes
Other Study ID Numbers: MAT-02
2012-000450-63 ( EudraCT Number )
First Submitted: September 12, 2013
First Posted: September 19, 2013
Last Update Posted: September 27, 2017
Last Verified: September 2017

Keywords provided by Roger Tell, Karolinska University Hospital:
Melanoma
Interleukin-2
Dendritic cell vaccination
Lymphodepletion
Adoptive cell transfer
T cells
Tumor infiltrating lymphocytes
Fludarabine
IL-2
Cyclophosphamide
Phase I study
Monocytes
Autologous
NY-ESO-1

Additional relevant MeSH terms:
Melanoma
Nevi and Melanomas
Interleukin-2
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Cyclophosphamide
Fludarabine phosphate
Fludarabine
Vaccines
Vidarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents